TherapeuticsMD, Inc. filed Definitive Additional Materials (DEFA14A) on November 20, 2026, providing stockholders with a notice of the company's Annual Meeting of Stockholders scheduled for December 30, 2026 at 8:00 AM Eastern Time.
Key Highlights
- Meeting date: The Annual Meeting of Stockholders is set for Wednesday, December 30, 2026 at 8:00 AM Eastern Time, to be held live via the Internet.
- Record date: Stockholders of record as of November 16, 2026 are eligible to vote.
- Director election: Four nominees are proposed for election: Tommy G. Thompson, Cooper C. Collins, Gail K. Naughton Ph.D., and Justin Roberts.
- Executive compensation: Stockholders will vote on a non-binding advisory basis on compensation of named executive officers for the fiscal year ended December 31, 2025.
- Auditor ratification: The board recommends ratifying Carr, Riggs & Ingram, L.L.C. as independent auditor for the fiscal year ending December 31, 2026.
- Board recommendation: The Board of Directors recommends a vote FOR on Proposals 1, 2, and 3.
TherapeuticsMD Annual Stockholder Vote: Agenda and Board Positions
TherapeuticsMD, Inc. (NASDAQ:TXMD), a pharmaceutical company, filed Definitive Additional Materials with the SEC on November 20, 2026, notifying eligible stockholders about the upcoming Annual Meeting of Stockholders. According to the filing, the meeting will be held exclusively online on December 30, 2026, and stockholders must register in advance to attend and participate.
The filing outlines three formal proposals on which the Board of Directors recommends a vote in favor. Proposal 1 calls for the election of four directors to serve until the next annual meeting or until successors are duly elected and qualified. The four nominees identified in the filing are Tommy G. Thompson, Cooper C. Collins, Gail K. Naughton Ph.D., and Justin Roberts. Proposal 2 asks stockholders to approve, on a non-binding advisory basis, the compensation of named executive officers for the fiscal year ended December 31, 2025. Proposal 3 seeks ratification of Carr, Riggs & Ingram, L.L.C. as the company's independent registered public accounting firm for the fiscal year ending December 31, 2026.
The filing notes that proxy materials are available on the Internet under SEC rules, and that stockholders who want a paper or email copy may request one at no charge. The filing also states that this communication "presents only an overview of the more complete proxy materials" and that it "is not a ballot" and cannot be used to vote shares. Stockholders will need a 12-digit control number to access the voting platform and to register for the online meeting.
What Was Disclosed
TherapeuticsMD filed a DEFA14A on November 20, 2026, alerting stockholders of record as of November 16, 2026 to an Annual Meeting on December 30, 2026, covering director elections, an advisory compensation vote, and auditor ratification, with the board recommending FOR on all three formal proposals.



Please wait processing your request...